off
FDA Panel unanimously votes in favor of Collegium’s Abuse-deterrent Analgesic
In fact, Purdue was supposed to appear before the FDA’s advisory panel of analgesic experts on July 7 to review data from its supplemental application for abuse-deterrent OxyContin, but chose to delay the meeting.
Posted On Sep 15 2015
